Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis

被引：1
|
作者：
Blauvelt, A. [1 ]
Langley, R. [2 ]
Leonardi, C. [3 ]
Gordon, K. [4 ]
Luger, T. [5 ]
Ohtsuki, M. [6 ]
Nickoloff, B. [7 ]
Kerr, L. [7 ]
Mallbris, L. [7 ]
Reich, K. [8 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dalhousie Univ, Halifax, NS, Canada
[3] St Louis Univ, St Louis, MO 63103 USA
[4] Northwestern Univ, Feinberg Sch Med, St Louis, MO USA
[5] Univ Munster, Munster, Germany
[6] Jichi Med Univ, Shimotsuke, Japan
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Dermatologikum Hamburg & SCIderm Res Inst, Hamburg, Germany
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 09期
关键词：
D O I：
10.1016/j.jid.2016.06.408
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
388
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 50 条
  • [21] Exploring molecular transformation in psoriatic patients during 84 days of anti-IL-17A treatment
    Bertelsen, T.
    Ljungberg, C.
    Iversen, L.
    Johansen, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S76 - S76
  • [22] Transcriptomic analysis of plaque psoriasis during anti-IL-17A biologic therapy and drug withdrawal
    Chen, L.
    Zhang, L.
    Xu, X.
    Xu, Q.
    Xue, F.
    Hao, P.
    Li, X.
    Zheng, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S341 - S341
  • [23] Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients
    Egawa, G.
    Honda, T.
    Kabashima, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (02) : 259 - 259
  • [24] Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity potential according to human in vitro assays
    Karle, A.
    Spindeldreher, S.
    Kolbinger, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E164 - E164
  • [25] Immunogenicity of tumour necrosis factor inhibitors in patients with psoriasis receiving long-term treatment
    Meyer, M. W.
    Zachariae, C.
    Bendtzen, K.
    Skov, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E17 - E17
  • [26] Serum lipidomic study of long-chain fatty acids in psoriasis patients prior to and after anti-IL-17A monoclonal antibody treatment by quantitative GC‒MS analysis with in situ extraction
    XiaoYu Guo
    Jianglu Zhou
    Hong Yu
    Han Cao
    Xia Li
    Qing Hu
    YunQiu Yu
    Lipids in Health and Disease, 23
  • [27] Safety profile of ixekizumab, an anti-IL-17 monoclonal antibody, in chronic plaque psoriasis patients after at least 1 year of open label treatment
    Gordon, Kenneth
    Leonardi, Craig
    Braun, Daniel
    Cameron, Gregory
    Erickson, Janelle
    Lebwohl, Mark
    Heffernan, Michael
    Banerjee, Subhashis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB184 - AB184
  • [28] Assessment of the immune response to novel Anti-IL-17A antibody, secukinumab, after intravenous and subcutaneous application in healthy subjects and patients
    Klein, U.
    Kolbinger, F.
    Liang, E.
    Vogel, B.
    Bruin, G.
    Lloyd, P.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 134 - 134
  • [29] Serum lipidomic study of long-chain fatty acids in psoriasis patients prior to and after anti-IL-17A monoclonal antibody treatment by quantitative GC-MS analysis with in situ extraction
    Guo, Xiaoyu
    Zhou, Jianglu
    Yu, Hong
    Cao, Han
    Li, Xia
    Hu, Qing
    Yu, Yunqiu
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [30] PHARMACOKINETICS OF ETRETIN AND ETRETINATE DURING LONG-TERM TREATMENT OF PSORIASIS PATIENTS
    LARSEN, FG
    JAKOBSEN, P
    LARSEN, CG
    KRAGBALLE, K
    NIELSENKUDSK, F
    PHARMACOLOGY & TOXICOLOGY, 1988, 62 (03): : 159 - 165
12345